Solid Biosciences Llc Stock Performance
| SLDB Stock | USD 3.32 0.14 4.40% |
The entity has a beta of 0.031, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Solid Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Solid Biosciences is expected to be smaller as well. At this point, Solid Biosciences LLC has a negative expected return of -0.77%. Please make sure to validate Solid Biosciences' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Solid Biosciences LLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Solid Biosciences LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.22) | Five Day Return 0.32 | Year To Date Return (18.46) | Ten Year Return (99.06) | All Time Return (99.06) |
Last Split Factor 1:15 | Last Split Date 2022-10-28 |
1 | Solid Biosciences Inc. Receives 15.67 Consensus Target Price from Brokerages - MarketBeat | 11/08/2024 |
2 | Disposition of 72 shares by Paul Herzich of Solid Biosciences subject to Rule 16b-3 | 12/02/2024 |
3 | Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 12/03/2024 |
4 | Alexander Cumbo Sells 11,114 Shares of Solid Biosciences Inc. Stock | 12/06/2024 |
5 | Solid Biosciences Rating Increased to Strong-Buy at Citizens Jmp | 12/11/2024 |
6 | Disposition of 3255 shares by Smith Ian F of Solid Biosciences subject to Rule 16b-3 | 01/03/2025 |
7 | Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestation... | 01/07/2025 |
8 | Disposition of 11250 shares by Tan Kevin of Solid Biosciences subject to Rule 16b-3 | 01/08/2025 |
9 | Solid Biosciences Inc. CFO Kevin Tan Sells 4,073 Shares | 01/14/2025 |
10 | Cantor Fitzgerald Comments on SLDB FY2025 Earnings - MarketBeat | 01/22/2025 |
11 | Disposition of 388 shares by Ilan Ganot of Solid Biosciences subject to Rule 16b-3 | 01/27/2025 |
12 | Disposition of 144 shares by Ilan Ganot of Solid Biosciences at 3.1096 subject to Rule 16b-3 | 01/28/2025 |
13 | Disposition of 1142 shares by Ilan Ganot of Solid Biosciences at 5.2999 subject to Rule 16b-3 | 01/30/2025 |
| Begin Period Cash Flow | 155.4 M |
Solid |
Solid Biosciences Relative Risk vs. Return Landscape
If you would invest 566.00 in Solid Biosciences LLC on November 4, 2024 and sell it today you would lose (234.00) from holding Solid Biosciences LLC or give up 41.34% of portfolio value over 90 days. Solid Biosciences LLC is currently does not generate positive expected returns and assumes 4.4958% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Solid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Solid Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Solid Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Solid Biosciences LLC, and traders can use it to determine the average amount a Solid Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1711
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLDB |
Estimated Market Risk
| 4.5 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Solid Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Solid Biosciences by adding Solid Biosciences to a well-diversified portfolio.
Solid Biosciences Fundamentals Growth
Solid Stock prices reflect investors' perceptions of the future prospects and financial health of Solid Biosciences, and Solid Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Solid Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | (19.34 M) | ||||
| Shares Outstanding | 39.95 M | ||||
| Price To Book | 0.79 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (76.56 M) | ||||
| EBITDA | (93.43 M) | ||||
| Net Income | (96.02 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 26.27 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (94.18 M) | ||||
| Earnings Per Share | (3.04) X | ||||
| Market Capitalization | 127.06 M | ||||
| Total Asset | 164.94 M | ||||
| Retained Earnings | (658.75 M) | ||||
| Working Capital | 115.22 M | ||||
About Solid Biosciences Performance
By analyzing Solid Biosciences' fundamental ratios, stakeholders can gain valuable insights into Solid Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Solid Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Solid Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 33.64 | 29.90 | |
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (0.87) | (0.83) |
Things to note about Solid Biosciences LLC performance evaluation
Checking the ongoing alerts about Solid Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Solid Biosciences LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Solid Biosciences generated a negative expected return over the last 90 days | |
| Solid Biosciences has high historical volatility and very poor performance | |
| Solid Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (96.02 M) with loss before overhead, payroll, taxes, and interest of (76.56 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (94.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Solid Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1142 shares by Ilan Ganot of Solid Biosciences at 5.2999 subject to Rule 16b-3 |
- Analyzing Solid Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Solid Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Solid Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Solid Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Solid Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Solid Biosciences' stock. These opinions can provide insight into Solid Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |